Orexo Interim Report Q3 2019
Strong financials paving the way for broadening the business Q3 2019 highlights · Total net revenues of SEK 231.2 million (216.6), up 6.7 percent · Zubsolv® US net revenues of SEK 182.7 million (165.4), up 10.4 percent in SEK and 3.0 percent in local currency · EBITDA of SEK 114.1 million (39.8), up 186.7 percent. EBITDA ex Abstral® of SEK 71.7 million (-8.9). · US EBIT of SEK 93.4 million (55.6), up 68.0 percent · Cash flow from operating activities of SEK 135.7 million (24.5), building a cash balance of SEK 812.9 million (516.6) · Net earnings of SEK 111.7 million (